177 related articles for article (PubMed ID: 11394901)
1. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity.
Pitarque M; von Richter O; Oke B; Berkkan H; Oscarson M; Ingelman-Sundberg M
Biochem Biophys Res Commun; 2001 Jun; 284(2):455-60. PubMed ID: 11394901
[TBL] [Abstract][Full Text] [Related]
2. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity.
Pitarque M; von Richter O; Rodríguez-Antona C; Wang J; Oscarson M; Ingelman-Sundberg M
Hum Mutat; 2004 Mar; 23(3):258-66. PubMed ID: 14974084
[TBL] [Abstract][Full Text] [Related]
3. Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6).
von Richter O; Pitarque M; Rodríguez-Antona C; Testa A; Mantovani R; Oscarson M; Ingelman-Sundberg M
Pharmacogenetics; 2004 Jun; 14(6):369-79. PubMed ID: 15247629
[TBL] [Abstract][Full Text] [Related]
4. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase.
Oscarson M; Gullstén H; Rautio A; Bernal ML; Sinues B; Dahl ML; Stengård JH; Pelkonen O; Raunio H; Ingelman-Sundberg M
FEBS Lett; 1998 Nov; 438(3):201-5. PubMed ID: 9827545
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M; Fukami T; Yamanaka H; Higashi E; Sakai H; Yoshida R; Kwon JT; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2006 Sep; 80(3):282-97. PubMed ID: 16952495
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.
Oscarson M; McLellan RA; Gullstén H; Agúndez JA; Benítez J; Rautio A; Raunio H; Pelkonen O; Ingelman-Sundberg M
FEBS Lett; 1999 Oct; 460(2):321-7. PubMed ID: 10544257
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.
Paschke T; Riefler M; Schuler-Metz A; Wolz L; Scherer G; McBride CM; Bepler G
Toxicology; 2001 Nov; 168(3):259-68. PubMed ID: 11684323
[TBL] [Abstract][Full Text] [Related]
8. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.
Fukami T; Nakajima M; Sakai H; McLeod HL; Yokoi T
Pharmacogenomics J; 2006; 6(6):401-12. PubMed ID: 16636685
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.
Ariyoshi N; Takahashi Y; Miyamoto M; Umetsu Y; Daigo S; Tateishi T; Kobayashi S; Mizorogi Y; Loriot MA; Stücker I; Beaune P; Kinoshita M; Kamataki T
Pharmacogenetics; 2000 Nov; 10(8):687-93. PubMed ID: 11186131
[TBL] [Abstract][Full Text] [Related]
10. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.
Oscarson M; McLellan RA; Gullstén H; Yue QY; Lang MA; Bernal ML; Sinues B; Hirvonen A; Raunio H; Pelkonen O; Ingelman-Sundberg M
FEBS Lett; 1999 Apr; 448(1):105-10. PubMed ID: 10217419
[TBL] [Abstract][Full Text] [Related]
11. Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies.
Nowak MP; Sellers EM; Tyndale RF
Clin Pharmacol Ther; 1998 Oct; 64(4):378-83. PubMed ID: 9797794
[TBL] [Abstract][Full Text] [Related]
12. Determination of coumarin metabolism in Turkish population.
Cok I; Aygün Kocabaş N; Cholerton S; Karakaya AE; Sardaş S
Hum Exp Toxicol; 2001 Apr; 20(4):179-84. PubMed ID: 11393269
[TBL] [Abstract][Full Text] [Related]
13. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
Yoshida R; Nakajima M; Nishimura K; Tokudome S; Kwon JT; Yokoi T
Clin Pharmacol Ther; 2003 Jul; 74(1):69-76. PubMed ID: 12844137
[TBL] [Abstract][Full Text] [Related]
14. 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression.
Wang J; Pitarque M; Ingelman-Sundberg M
Biochem Biophys Res Commun; 2006 Feb; 340(2):491-7. PubMed ID: 16378601
[TBL] [Abstract][Full Text] [Related]
15. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.
Xu C; Rao YS; Xu B; Hoffmann E; Jones J; Sellers EM; Tyndale RF
Biochem Biophys Res Commun; 2002 Jan; 290(1):318-24. PubMed ID: 11779172
[TBL] [Abstract][Full Text] [Related]
16. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
17. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.
Mwenifumbo JC; Myers MG; Wall TL; Lin SK; Sellers EM; Tyndale RF
Pharmacogenet Genomics; 2005 Mar; 15(3):189-92. PubMed ID: 15861044
[TBL] [Abstract][Full Text] [Related]
18. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T; Nakajima M; Yoshida R; Tsuchiya Y; Fujiki Y; Katoh M; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
[TBL] [Abstract][Full Text] [Related]
19. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians.
Inoue K; Yamazaki H; Shimada T
Arch Toxicol; 2000 Jan; 73(10-11):532-9. PubMed ID: 10663384
[TBL] [Abstract][Full Text] [Related]
20. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
